In Turkey as well as in the whole world, cardiac catheterization is an invasive intervention that is being increasingly used both for diagnosis and treatment. With technological and pharmacologic development and experience, the indications for this intervention are ever increasing. This invasive intervention brings, of course, some complications with it. These may range from local ones to death. In this study the authors analyzed the local cardiac complications and those related to other systems that they encountered in 10,445 catheterizations conducted for diagnosis and treatment in their clinic over a 26-month period. They found the rate of all complications to be 3.54% (2.05% diagnostic, 9.1% therapeutic). Of these complications, 1.89% (0.80% diagnostic, 6.02% therapeutic) were cardiac, 1.27% (0.97% diagnostic, 2.4% therapeutic) local. They found that the ratios of death were 0.09% for diagnostic interventions, 1.13% for therapeutic interventions, and 0.31% altogether. In the diagnostic group 0.02% required urgent coronary bypass surgery, and 0.41% needed urgent coronary bypass surgery in the therapeutic group. In conclusion, despite the noticeable changes in patient profile and application, the ratios for cardiac catheterization have changed little over the years.
GİRİŞ ve AMAÇ: Önceden, koroner yavaş akışın (KYA) erkek cinsiyet, yüksek BMI ve sigara kullanımı ile ilgili olduğu bildirilmişti. Ancak KYA, kadınlarda da görülen bir klinik durumdur ve bu konuda herhangi bir çalışma yapılmamıştır. Bu çalışmada kadın hastalarda KYA 'nın belirleyicilerini araştırmayı amaçladık. 40'ı normal (ortalama yaş: 51.9 ± 5.2 yıl) ve 40 'I KYA (ortalama yaş: 54.6 ± 7.7 yıl) toplam 80 kadın hasta seçildi. TIMI frame sayıları hesaplandı ve demografik özellikler, komorbiditeler ve ilaç kullanımı ile ilgili veriler toplandı. CSF, frame sayısı> 27 olarak tanımlandı. BULGULAR: KYA grubunda diyabetes mellitus (DM) yüzdesi anlamlı olarak yüksekti (% 52.5'e karşılık% 22.5; p: 0.005). DM, çok değişkenli lojistik regresyon analizinde KYA 'lı kadın hastaların anlamlı belirleyicisi olarak bulundu (O.R: 3.44,% 95 CI: 1.14-10.36; p: 0.028). TARTIŞMA ve SONUÇ: KYA 'lı kadın hastalarda DM'nin anlamlı derecede arttığını ve çok değişkenli analizde KYA 'nın bağımsız belirleyicisi olduğunu bulduk. Anahtar Kelimeler: kadın hastalar, koroner yavaş akım, klinik belirleyiciler ABSTRACT INTRODUCTION: Previously, the coronary slow flow (CSF) has been reported to be related to male sex, high BMI, and smoking. However, CSF is a clinical condition seen in women and no studies have been conducted on this subject. We aimed to investigate predictors of coronary slow flow in female patients.
YÖNTEM ve GEREÇLER:
METHODS:A total of 80 female patients, 40 of whom were normal (mean age: 51.9±5.2 years) and 40 with coronary slow flow(mean age: 54.6 ±7.7 years) were selected. TIMI frame counts were calculated, and data on demographics, comorbidities, and medication use were collected. CSF was defined as frame count >27.
RESULTS:Percentage of diabetes mellitus (DM) was significantly higher in the CSF group ( 52.5 % vs. 22.5 %; p: 0.005). DM was found to be significant predictor of female patients with CSF in the multivariate logistic regression analysis (O.R: 3.44, p: 0.028).
DISCUSSION and CONCLUSION:We found that DM was significantly increased and only independent predictor of CSF in female patients with CSF.
K Ka ad dı ın n H Ha as st ta al la ar rd da a K Ko or ro on ne er r Y Ya av va aş ş AAk kı ım mı ın n K Kl li in ni ik k B Be el li ir rl le ey yi ic ci il le er ri i C Cl li in ni ic ca al l P Pr re ed di ic ct to or rs s o of f C Co or ro on na ar ry y S Sl lo ow w F Fl lo ow w i in n F Fe em ma al le e P Pa at ti ie en nt ts s
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.